IL-10-Inducing Compounds for Stable Immune Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for immune-mediated diseases focus on suppressing immunity and inflammation but fail to restore dominant immune regulation, leading to treatment resistance and relapse, and do not improve patient quality of life or reduce side effects.
Innovation Solution
Development of compounds that induce the production of interleukin-10 (IL-10) by immune cells, particularly B cells, T cells, and myeloid cells, using specific activation pathways, to promote a stable immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If immunosuppressive drugs are used to suppress immunity and inhibit inflammation, then inflammation is reduced, but treatment resistance and relapse occur due to failure to restore dominant immune regulation
Solution Approach 1:
Instead of suppressing immunity to reduce inflammation, the invention inverts the approach by activating immune cells to produce IL-10, an anti-inflammatory cytokine. This shifts from direct suppression to indirect regulation through cytokine induction, addressing both inflammation reduction and treatment stability by restoring immune regulation rather than merely suppressing immune function.
Solution Approach 2:
The invention introduces IL-10 as an intermediary substance that mediates between immune cells and inflammation. By inducing immune cells to produce IL-10, the treatment uses this cytokine as a mediator to achieve anti-inflammatory effects while maintaining immune regulation, thereby improving treatment reliability and reducing relapse.
2Object-affected harmful factors
If immunosuppressive drugs are used to treat immune-mediated diseases, then inflammation is suppressed, but patient quality of life does not improve and side effects increase
Solution Approach 1:
The invention enables immune cells to self-regulate inflammation by inducing them to produce IL-10. This self-service mechanism allows the immune system to control its own inflammatory response through endogenous cytokine production, reducing reliance on external immunosuppressive drugs and their associated side effects while improving patient quality of life.
3Object-affected harmful factors
If conventional therapy focuses on suppressing immunity, then inflammation is reduced, but dominant immune regulation is not restored leading to treatment failure
Solution Approach 1:
The invention inverts the conventional suppression approach by actively inducing immune cells to produce anti-inflammatory cytokines. This inversion transforms the treatment strategy from passive suppression to active restoration of immune regulation, addressing both inflammation control and long-term treatment reliability.
Solution Approach 2:
The invention changes the key parameter from immune suppression levels to IL-10 production levels. By shifting the therapeutic parameter from suppressing immune activity to inducing specific cytokine production, the treatment achieves both inflammation reduction and restoration of immune regulation, improving overall treatment reliability.
Data Source
AI summary
The present invention relates to a compound of formula (I) and its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relates to the use of the induced immune cells in the prevention and/or treatment of immune-mediated diseases.